Company intelligence / Profile preview
Shanghai Zhangjiang Biotechnology
Shanghai, Shanghai, Chinafd-zj.com ↗
- Ownership
- Private
- Employees
- ~600
- Development stage
- Other
01
Overview
The company has several approved products including hemoporfin for port wine stain and aminolevulinic acid hydrochloride for various indications. Multiple ADC candidates are in clinical trials, with FDA022 (HER2 x Top I) in Phase 2, and FDA018 (Trop-2 x Top I) and FZ-AD005 (DLL3 x Top I) in Phase 1.
- Therapeutic areas
- GastroenterologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodiesBiosimilarsFusion proteinsLiposomal drugsSmall molecule drugsGenetic engineering drugsPhotodynamic technology drugsNano technology drugsOral solid preparation technology drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Zhangjiang Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Zhangjiang Biotechnology.